Abstract
Background: Development of innovative drugs for melanoma is occurring rapidly. These drugs are often associated with marginal prolongation of overall survival, as well as increased toxicity profiles. Therefore, HTA agencies increasingly require information on health related quality of life (HRQoL) for the assessment of such drugs. Objectives: This study explored
... read more